Bills · 2025-2026 Regular Session
Relating to: coverage of nonopioid drug alternatives for the treatment and management of pain.
Drugs Health services department of — Administration Insurance — Commissioner office of Insurance — Health Public employee — Group insurance United states — Food and drug administration
- Introduced, stopped here
- Passes Senate, not reached
- Passes Assembly, not reached
- Governor signs, not reached
- Law, not reached
Unfamiliar terms? Glossary
What this bill does
Plain-language analysis by the nonpartisan Legislative Reference Bureau
This bill requires health care insurance plans and self-insured governmental health plans that provide drug coverage to develop and implement a pain management access plan to ensure adequate coverage and access to a broad spectrum of pain management alternatives to opioid drugs. Under the bill, the health care plan or self-insured plan must provide coverage for at least two prescription medication treatment options that are approved by the U.S. Food and Drug Administration for the treatment or management of pain and are not schedule I, II, or III controlled substances. The health care plan or self-insured plan must also provide coverage for at least three alternative nonpharmacological treatment modalities. The bill prohibits the health care plan or self-insured plan from establishing utilization controls for clinically appropriate, FDA-approved nonopioid drugs or drug products that are more restrictive or extensive than utilization controls applicable to an opioid or narcotic drug. Also under the bill, the health care plan or self-insured plan must provide information about the pain management access plan to enrollees and health care providers and make the plan publicly available on its website.
The bill prohibits the Department of Health Services from disadvantaging or discouraging the inclusion on its preferred drug list of a nonopioid drug that is approved by the FDA for the treatment or management of pain relative to the inclusion of an opioid or narcotic drug for the treatment or management of pain.
This proposal may contain a health insurance mandate requiring a social and financial impact report under s. 601.423, stats.
Sponsors
Registered lobbying interests · 12
Organizations that registered lobbying activity on this bill with the Wisconsin Ethics Commission. Registration means interest, not a position for or against. Official record
- Alliance of Health Insurers, U.A.
- CareSource Wisconsin
- Chiropractic Society of Wisconsin
- Coalition of Wisconsin Aging Groups
- Elevance Health, and its affiliates dba Anthem Blue Cross Blue Shield
- Metropolitan Milwaukee Association of Commerce
- Pharmaceutical Care Management Association (PCMA)
- Vertex Pharmaceuticals
- Wisconsin Association of Health Plans
- Wisconsin Chiropractic Association
- Wisconsin Manufacturers & Commerce
- Wisconsin Naturopathic Doctors Association
Votes
Senate: Report passage by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 2, Noes 3
Failed 2–3 Jan 22, 2026 official source full pageNo individual roll call was recorded for this vote. Committee votes and some older sessions record totals only.
Full history
- Oct 2, 2025 · Senate
Introduced by Senators James, Dassler-Alfheim and Keyeski; cosponsored by Representatives Moses, Armstrong, Behnke, Duchow, Gundrum, Knodl, Melotik, Mursau, O'Connor, Wichgers and Murphy
- Oct 2, 2025 · Senate
Read first time and referred to Committee on Mental Health, Substance Abuse Prevention, Children and Families
- Oct 7, 2025 · Senate
Commissioner of Insurance report received pursuant to s.601.423(2), Wisconsin Statutes
- Oct 8, 2025 · Senate
Public hearing held
- Dec 16, 2025 · Senate
Senate Amendment 1 offered by Senator James
- Jan 22, 2026 · Senate
Senator Keyeski withdrawn as a coauthor
- Jan 22, 2026 · Senate
Executive action taken
- Jan 22, 2026 · Senate
Report passage by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 2, Noes 3
- Jan 22, 2026 · Senate
Available for scheduling
- Mar 23, 2026 · Senate
Failed to pass pursuant to Senate Joint Resolution 1